Jacob Chacko - Jul 10, 2023 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Stock symbol
ORIC
Transactions as of
Jul 10, 2023
Transactions value $
-$125,499
Form type
4
Date filed
7/11/2023, 09:28 PM
Previous filing
Jul 7, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Sale -$84.2K -10.5K -1.32% $8.01 786K Jul 10, 2023 Direct F1, F2
transaction ORIC Common Stock Sale -$41.3K -5.16K -0.66% $8.01 781K Jul 11, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 10,508 shares sold in the price range of $8.00 to $8.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 5,156 shares sold in the price range of $8.00 to $8.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.